IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
Rhea-AI Summary
IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.
The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.
The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.
Positive
- Development of potentially breakthrough next-generation cancer immunotherapy platform
- Early positive preclinical findings in multiple cancer types (AML and B-ALL)
- Platform demonstrates capability to target multiple cancer antigens
Negative
- Technology still in early preclinical stage
- No clinical efficacy data available yet
News Market Reaction
On the day this news was published, INAB declined 15.35%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.
“T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis and low IL-6 secretion, representing a powerful modality with the potential to overcome the limitations of current CD-3 based engager therapies,” said William Ho, CEO, and co-founder of IN8bio. Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the capacity for significant cell expansion and the specificity of bispecific engagers to drive a potent, targeted immune response against multiple target antigens. These early findings in AML and B-ALL support our broader strategy to harness the unique biology of these cells across a range of cancers.”
AACR Poster Presentation Details
Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy
Abstract Presentation Number: 7321 (Poster Board 7)
Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies
Session Date and Time: Wednesday, April 30, 2025, 9:00 AM – 12:00 PM CT
For more details visit: www.aacr.org/meeting/aacr-annual-meeting-2025/abstracts.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
What new technology will IN8bio (INAB) present at AACR 2025?
What advantages does IN8bio's gamma-delta T cell platform offer over current therapies?
Which cancer types has IN8bio's gamma-delta T cell platform shown early results in?
When and where will IN8bio present their gamma-delta T cell engager data?
